Given that SARS-CoV-2 is predominantly a respiratory pathogen, could a nebulized vaccine be more effective in terms of bioavailability and function?
Single-domain antibodies have been investigated as potential therapeutics for influenza, RSV and HIV in addition to coronaviruses. SARS-CoV-2 mainly targets the respiratory tract, hence the development of vaccines directed to the respiratory epithelia and lung parenchyma using a nebulizer has been considered to maximize bioavailability and function.207 Although active research against respiratory viruses has focused on aerosolized plasmid DNA vaccines, other forms of vaccine administration are currently further advanced in clinical trials.203 Veterinary medicine commonly uses aerosolized coronavirus vaccines for chicken farms.208